Epiomic Epidemiology Series: Peripheral Arterial Disease Forecast in 22 Major Markets 2018–2028

July 2018 | 102 pages | ID: EE4CA3136CCEN
Black Swan Analysis limited

Abstracts

Black Swan Analysis Epiomic Epidemiology Series Forecast Report on Peripheral Arterial Disease (PAD) in 22 Major Markets

Peripheral Arterial disease (PAD) is an occlusion of the peripheral arteries and is widely viewed as a measure of an individual's global systemic atherosclerotic burden. Typically, it is defined as an ankle-brachial pressure index (APBI) ratio of 0.9. PAD can also be known as peripheral arterial occlusive disease, arteriosclerosis obliterans, lower extremity occlusive disease and peripheral vascular disease.

This report provides the current prevalent population for PAD across 22 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Sweden, Greece, Russia, Turkey, Saudi Arabia, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main patient features and co-morbidities of PAD have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for PAD include:

• Hypertension
• Family history of PAD
• Dyslipidaemia
• Obesity
• Diabetes
• Lower limb ischaemia
• Myocardial infarction
• Coronary artery disease (CAD)

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Ability to quantify patient populations in global PAD market to target the development of future products, pricing strategies and launch plans.
• Further insight into the prevalence of the subdivided types of PAD and identification of patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Better understanding on the impact of specific co-morbid conditions on the prevalent population of PAD patients.
• Identification of PAD patient sub-populations that require treatment.
• Better understanding of the specific markets that have the largest number of PAD patients.

Contents

INTRODUCTION

CAUSE OF THE DISEASE

RISK FACTORS & PREVENTION

DIAGNOSIS OF THE DISEASE

VARIATION BY GEOGRAPHY/ETHNICITY

DISEASE PROGNOSIS & CLINICAL COURSE

KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE

METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS

TOP-LINE PREVALENCE FOR PERIPHERAL ARTERIAL DISEASE

FEATURES OF PERIPHERAL ARTERIAL DISEASE

PATIENT PARAMETERS

COMORBIDITIES OF PAD PATIENTS

COMORBIDITIES OF PAD PATIENTS WITH INTERMITTENT CLAUDICATION

ABBREVIATIONS USED IN THE REPORT

OTHER BLACK SWAN SERVICES & SOLUTIONS

REPORTS & PUBLICATIONS

ONLINE EPIDEMIOLOGY DATABASES

ONLINE PHARMACEUTICAL PRICING DATABASE

REFERENCES

APPENDIX

List Of Tables

LIST OF TABLES AND FIGURES

Table 1. Fontaine Classification System for PAD
Table 2. Rutherford Classification System for PAD
Table 3. Society for Vascular Surgery WIfI for PAD classification
Table 4. Society for Vascular Surgery TASC II Classification for PAD
Table 5. Prevalence of PAD, total (000s)
Table 6. Prevalence of PAD, males (000s)
Table 7. Prevalence of PAD, females (000s)
Table 8. Patients with PAD by severity, total (000s)
Table 9. Patients with PAD by size of vessels involved, total (000s)
Table 10. Patients with PAD by presence of symptoms, total (000s)
Table 11. PAD patients with intermittent claudication by IC profile, total (000s)
Table 12. PAD patients with intermittent claudication by grade of symptoms, total (000s)
Table 13. Incidence of critical limb ischaemia in PAD patients with intermittent claudication, total (000s)
Table 14. PAD patients with acute limb ischaemia by 1-year outcome, total (000s)
Table 15. Patients with PAD by BMI status, total (000s)
Table 16. Patients with PAD by total cholesterol level, total (000s)
Table 17. Patients with PAD by LDL level, total (000s)
Table 18. Patients with PAD by smoking status, total (000s)
Table 19. PAD patients with diabetes, total (000s)
Table 20. PAD patients with arterial hypertension, total (000s)
Table 21. PAD patients with chronic heart failure, total (000s)
Table 22. PAD patients with coronary heart disease, total (000s)
Table 23. PAD patients with angina, total (000s)
Table 24. PAD patients with stroke, total (000s)
Table 25. PAD patients with elevated CRP, total (000s)
Table 26. PAD patients with intermittent claudication and diabetes, total (000s)
Table 27. PAD patients with intermittent claudication and hypertension, total (000s)
Table 28. PAD patients with intermittent claudication and hyperlipidaemia, total (000s)
Table 29. PAD patients with intermittent claudication and a history of myocardial infarction, total (000s)
Table 30. PAD patients with intermittent claudication and angina, total (000s)
Table 31. Abbreviations and acronyms used in the report
Table 32. USA prevalence of PAD by 5-yr age cohort, males (000s)
Table 33. USA prevalence of PAD by 5-yr age cohort, females (000s)
Table 34. Canada prevalence of PAD by 5-yr age cohort, males (000s)
Table 35. Canada prevalence of PAD by 5-yr age cohort, females (000s)
Table 36. France prevalence of PAD by 5-yr age cohort, males (000s)
Table 37. France prevalence of PAD by 5-yr age cohort, females (000s)
Table 38. Germany prevalence of PAD by 5-yr age cohort, males (000s)
Table 39. Germany prevalence of PAD by 5-yr age cohort, females (000s)
Table 40. Italy prevalence of PAD by 5-yr age cohort, males (000s)
Table 41. Italy prevalence of PAD by 5-yr age cohort, females (000s)
Table 42. Spain prevalence of PAD by 5-yr age cohort, males (000s)
Table 43. Spain prevalence of PAD by 5-yr age cohort, females (000s)
Table 44. UK prevalence of PAD by 5-yr age cohort, males (000s)
Table 45. UK prevalence of PAD by 5-yr age cohort, females (000s)
Table 46. Poland prevalence of PAD by 5-yr age cohort, males (000s)
Table 47. Poland prevalence of PAD by 5-yr age cohort, females (000s)
Table 48. Netherlands prevalence of PAD by 5-yr age cohort, males (000s)
Table 49. Netherlands prevalence of PAD by 5-yr age cohort, females (000s)
Table 50. Sweden prevalence of PAD by 5-yr age cohort, males (000s)
Table 51. Sweden prevalence of PAD by 5-yr age cohort, females (000s)
Table 52. Greece prevalence of PAD by 5-yr age cohort, males (000s)
Table 53. Greece prevalence of PAD by 5-yr age cohort, females (000s)
Table 54. Russia prevalence of PAD by 5-yr age cohort, males (000s)
Table 55. Russia prevalence of PAD by 5-yr age cohort, females (000s)
Table 56. Turkey prevalence of PAD by 5-yr age cohort, males (000s)
Table 57. Turkey prevalence of PAD by 5-yr age cohort, females (000s)
Table 58. Saudi Arabia prevalence of PAD by 5-yr age cohort, males (000s)
Table 59. Saudi Arabia prevalence of PAD by 5-yr age cohort, females (000s)
Table 60. Japan prevalence of PAD by 5-yr age cohort, males (000s)
Table 61. Japan prevalence of PAD by 5-yr age cohort, females (000s)
Table 62. China prevalence of PAD by 5-yr age cohort, males (000s)
Table 63. China prevalence of PAD by 5-yr age cohort, females (000s)
Table 64. South Korea prevalence of PAD by 5-yr age cohort, males (000s)
Table 65. South Korea prevalence of PAD by 5-yr age cohort, females (000s)
Table 66. India prevalence of PAD by 5-yr age cohort, males (000s)
Table 67. India prevalence of PAD by 5-yr age cohort, females (000s)
Table 68. Australia prevalence of PAD by 5-yr age cohort, males (000s)
Table 69. Australia prevalence of PAD by 5-yr age cohort, females (000s)
Table 70. Brazil prevalence of PAD by 5-yr age cohort, males (000s)
Table 71. Brazil prevalence of PAD by 5-yr age cohort, females (000s)
Table 72. Mexico prevalence of PAD by 5-yr age cohort, males (000s)
Table 73. Mexico prevalence of PAD by 5-yr age cohort, females (000s)
Table 74. Argentina prevalence of PAD by 5-yr age cohort, males (000s)
Table 75. Argentina prevalence of PAD by 5-yr age cohort, females (000s)